[1]
Castelli, W.P.; Anderson, K.; Wilson, P.W.; Levy, D. Lipids and risk of coronary heart disease. The Framingham Study. Ann. Epidemiol., 1992, 2(1-2), 23-28.
[2]
Cullen, P.; Schulte, H.; Assmann, G. The Münster Heart Study (PROCAM): total mortality in middle-aged men is increased at low total and LDL cholesterol concentrations in smokers but not in nonsmokers. Circulation, 1997, 96(7), 2128-2136.
[3]
Sharrett, A.R.; Ballantyne, C.M.; Coady, S.A.; Heiss, G.; Sorlie, P.D.; Catellier, D.; Patsch, W. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The atherosclerosis risk in communities (ARIC) study. Circulation, 2001, 104(10), 1108-1113.
[4]
Rader, D.J.; Hovingh, G.K. HDL and cardiovascular disease. Lancet, 2014, 384(9943), 618-625.
[5]
Scott, R.; O’Brien, R.; Fulcher, G.; Pardy, C.; D’Emden, M.; Tse, D.; Taskinen, M.R.; Ehnholm, C.; Keech, A. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the fenofibrate intervention and event lowering in diabetes (FIELD) study. Diabetes Care, 2009, 32(3), 493-498.
[6]
Boden, W.E.; Probstfield, J.L.; Anderson, T.; Chaitman, B.R.; Desvignes-Nickens, P.; Koprowicz, K.; McBride, R.; Teo, K.; Weintraub, W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med., 2011, 365(24), 2255-2267.
[7]
Barter, P.J.; Caulfield, M.; Eriksson, M.; Grundy, S.M.; Kastelein, J.J.; Komajda, M.; Lopez-Sendon, J.; Mosca, L.; Tardif, J.C.; Waters, D.D.; Shear, C.L.; Revkin, J.H.; Buhr, K.A.; Fisher, M.R.; Tall, A.R.; Brewer, B. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med., 2007, 357(21), 2109-2122.
[8]
Calabresi, L.; Gomaraschi, M.; Franceschini, G. High-density lipoprotein quantity or quality for cardiovascular prevention? Curr. Pharm. Des., 2010, 16(13), 1494-1503.
[9]
Annema, W.; von Eckardstein, A. High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis. Circ. J., 2013, 77(10), 2432-2448.
[10]
Basso, F.; Freeman, L.; Knapper, C.L.; Remaley, A.; Stonik, J.; Neufeld, E.B.; Tansey, T.; Amar, M.J.; Fruchart-Najib, J.; Duverger, N.; Santamarina-Fojo, S.; Brewer, H.B., Jr Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations. J. Lipid Res., 2003, 44(2), 296-302.
[11]
Calabresi, L.; Gomaraschi, M.; Simonelli, S.; Bernini, F.; Franceschini, G. HDL and atherosclerosis: insights from inherited HDL disorders. Biochim. Biophys. Acta, 2015, 1851(1), 13-18.
[12]
Rye, K.A.; Clay, M.A.; Barter, P.J. Remodelling of high density lipoproteins by plasma factors. Atherosclerosis, 1999, 145(2), 227-238.
[13]
Huuskonen, J.; Olkkonen, V.M.; Jauhiainen, M.; Ehnholm, C. The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis, 2001, 155(2), 269-281.
[14]
Rosenson, R.S.; Brewer, H.B., Jr; Davidson, W.S.; Fayad, Z.A.; Fuster, V.; Goldstein, J.; Hellerstein, M.; Jiang, X.C.; Phillips, M.C.; Rader, D.J.; Remaley, A.T.; Rothblat, G.H.; Tall, A.R.; Yvan-Charvet, L. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation, 2012, 125(15), 1905-1919.
[15]
Schwartz, C.C.; VandenBroek, J.M.; Cooper, P.S. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J. Lipid Res., 2004, 45(9), 1594-1607.
[16]
Calabresi, L.; Gomaraschi, M.; Franceschini, G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler. Thromb. Vasc. Biol., 2003, 23(10), 1724-1731.
[17]
Nofer, J.R. Signal transduction by HDL: agonists, receptors, and signaling cascades. Handb. Exp. Pharmacol., 2015, 224, 229-256.
[18]
Kontush, A.; Chantepie, S.; Chapman, M.J. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler. Thromb. Vasc. Biol., 2003, 23(10), 1881-1888.
[19]
Shuhei, N.; Söderlund, S.; Jauhiainen, M.; Taskinen, M.R. Effect of HDL composition and particle size on the resistance of HDL to the oxidation. Lipids Health Dis., 2010, 9, 104.
[20]
Ashby, D.T.; Rye, K.A.; Clay, M.A.; Vadas, M.A.; Gamble, J.R.; Barter, P.J. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler. Thromb. Vasc. Biol., 1998, 18(9), 1450-1455.
[21]
Cuchel, M.; Rader, D.J. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation, 2006, 113(21), 2548-2555.
[22]
Khera, A.V.; Cuchel, M.; de la Llera-Moya, M.; Rodrigues, A.; Burke, M.F.; Jafri, K.; French, B.C.; Phillips, J.A.; Mucksavage, M.L.; Wilensky, R.L.; Mohler, E.R.; Rothblat, G.H.; Rader, D.J. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med., 2011, 364(2), 127-135.
[23]
Li, X.M.; Tang, W.H.; Mosior, M.K.; Huang, Y.; Wu, Y.; Matter, W.; Gao, V.; Schmitt, D.; Didonato, J.A.; Fisher, E.A.; Smith, J.D.; Hazen, S.L. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler. Thromb. Vasc. Biol., 2013, 33(7), 1696-1705.
[24]
Karathanasis, S.K.; Freeman, L.A.; Gordon, S.M.; Remaley, A.T. The Changing face of HDL and the best way to measure it. Clin. Chem., 2017, 63(1), 196-210.
[25]
Calabresi, L.; Baldassarre, D.; Castelnuovo, S.; Conca, P.; Bocchi, L.; Candini, C.; Frigerio, B.; Amato, M.; Sirtori, C.R.; Alessandrini, P.; Arca, M.; Boscutti, G.; Cattin, L.; Gesualdo, L.; Sampietro, T.; Vaudo, G.; Veglia, F.; Calandra, S.; Franceschini, G. Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation, 2009, 120(7), 628-635.
[26]
Sirtori, C.R.; Calabresi, L.; Franceschini, G.; Baldassarre, D.; Amato, M.; Johansson, J.; Salvetti, M.; Monteduro, C.; Zulli, R.; Muiesan, M.L.; Agabiti-Rosei, E. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation, 2001, 103(15), 1949-1954.
[27]
Calabresi, L.; Favari, E.; Moleri, E.; Adorni, M.P.; Pedrelli, M.; Costa, S.; Jessup, W.; Gelissen, I.C.; Kovanen, P.T.; Bernini, F.; Franceschini, G. Functional LCAT is not required for macrophage cholesterol efflux to human serum. Atherosclerosis, 2009, 204(1), 141-146.
[28]
Franceschini, G.; Calabresi, L.; Chiesa, G.; Parolini, C.; Sirtori, C.R.; Canavesi, M.; Bernini, F. Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice. Arterioscler. Thromb. Vasc. Biol., 1999, 19(5), 1257-1262.
[29]
Gomaraschi, M.; Baldassarre, D.; Amato, M.; Eligini, S.; Conca, P.; Sirtori, C.R.; Franceschini, G.; Calabresi, L. Normal vascular function despite low levels of high-density lipoprotein cholesterol in carriers of the apolipoprotein A-I(Milano) mutant. Circulation, 2007, 116(19), 2165-2172.
[30]
Gomaraschi, M.; Ossoli, A.; Castelnuovo, S.; Simonelli, S.; Pavanello, C.; Balzarotti, G.; Arca, M.; Di Costanzo, A.; Sampietro, T.; Vaudo, G.; Baldassarre, D.; Veglia, F.; Franceschini, G.; Calabresi, L. Depletion in LpA-I:A-II particles enhances HDL-mediated endothelial protection in familial LCAT deficiency. J. Lipid Res., 2017, 58(5), 994-1001.
[31]
Zanoni, P.; Khetarpal, S.A.; Larach, D.B.; Hancock-Cerutti, W.F.; Millar, J.S.; Cuchel, M.; DerOhannessian, S.; Kontush, A.; Surendran, P.; Saleheen, D.; Trompet, S.; Jukema, J.W.; De Craen, A.; Deloukas, P.; Sattar, N.; Ford, I.; Packard, C.; Majumder, A.; Alam, D.S.; Di Angelantonio, E.; Abecasis, G.; Chowdhury, R.; Erdmann, J.; Nordestgaard, B.G.; Nielsen, S.F.; Tybjærg-Hansen, A.; Schmidt, R.F.; Kuulasmaa, K.; Liu, D.J.; Perola, M.; Blankenberg, S.; Salomaa, V.; Männistö, S.; Amouyel, P.; Arveiler, D.; Ferrieres, J.; Müller-Nurasyid, M.; Ferrario, M.; Kee, F.; Willer, C.J.; Samani, N.; Schunkert, H.; Butterworth, A.S.; Howson, J.M.; Peloso, G.M.; Stitziel, N.O.; Danesh, J.; Kathiresan, S.; Rader, D.J. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science, 2016, 351(6278), 1166-1171.
[32]
Calabresi, L.; Nilsson, P.; Pinotti, E.; Gomaraschi, M.; Favari, E.; Adorni, M.P.; Bernini, F.; Sirtori, C.R.; Calandra, S.; Franceschini, G.; Tarugi, P. A novel homozygous mutation in CETP gene as a cause of CETP deficiency in a Caucasian kindred. Atherosclerosis, 2009, 205(2), 506-511.
[33]
Gomaraschi, M.; Ossoli, A.; Pozzi, S.; Nilsson, P.; Cefalù, A.B.; Averna, M.; Kuivenhoven, J.A.; Hovingh, G.K.; Veglia, F.; Franceschini, G.; Calabresi, L. eNOS activation by HDL is impaired in genetic CETP deficiency. PLoS One, 2014, 9(5), e95925.
[34]
Madsen, C.M.; Varbo, A.; Nordestgaard, B.G. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur. Heart J., 2017, 38(32), 2478-2486.
[35]
Marsche, G.; Saemann, M.D.; Heinemann, A.; Holzer, M. Inflammation alters HDL composition and function: implications for HDL-raising therapies. Pharmacol. Ther., 2013, 137(3), 341-351.
[36]
Laaksonen, R.; Ekroos, K.; Sysi-Aho, M.; Hilvo, M.; Vihervaara, T.; Kauhanen, D.; Suoniemi, M.; Hurme, R.; März, W.; Scharnagl, H.; Stojakovic, T.; Vlachopoulou, E.; Lokki, M.L.; Nieminen, M.S.; Klingenberg, R.; Matter, C.M.; Hornemann, T.; Jüni, P.; Rodondi, N.; Räber, L.; Windecker, S.; Gencer, B.; Pedersen, E.R.; Tell, G.S.; Nygård, O.; Mach, F.; Sinisalo, J.; Lüscher, T.F. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur. Heart J., 2016, 37(25), 1967-1976.
[37]
Sethi, A.A.; Sampson, M.; Warnick, R.; Muniz, N.; Vaisman, B.; Nordestgaard, B.G.; Tybjaerg-Hansen, A.; Remaley, A.T. High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. Clin. Chem., 2010, 56(7), 1128-1137.
[38]
Schlitt, A.; Schwaab, B.; Fingscheidt, K.; Lackner, K.J.; Heine, G.H.; Vogt, A.; Buerke, M.; Maegdefessel, L.; Raaz, U.; Werdan, K.; Jiang, X.C. Serum phospholipid transfer protein activity after a high fat meal in patients with insulin-treated type 2 diabetes. Lipids, 2010, 45(2), 129-135.
[39]
Gomaraschi, M.; Sinagra, G.; Serdoz, L.V.; Pitzorno, C.; Fonda, M.; Cattin, L.; Calabresi, L.; Franceschini, G. The plasma concentration of Lpa-I:A-II particles as a predictor of the inflammatory response in patients with ST-elevation myocardial infarction. Atherosclerosis, 2009, 202(1), 304-311.
[40]
Gomaraschi, M.; Ossoli, A.; Favari, E.; Adorni, M.P.; Sinagra, G.; Cattin, L.; Veglia, F.; Bernini, F.; Franceschini, G.; Calabresi, L. Inflammation impairs eNOS activation by HDL in patients with acute coronary syndrome. Cardiovasc. Res., 2013, 100(1), 36-43.
[41]
Sposito, A.C.; Carvalho, L.S.; Cintra, R.M.; Araújo, A.L.; Ono, A.H.; Andrade, J.M.; Coelho, O.R.; Quinaglia e Silva, J.C. Rebound inflammatory response during the acute phase of myocardial infarction after simvastatin withdrawal. Atherosclerosis, 2009, 207(1), 191-194.
[42]
Pitt, B.; Loscalzo, J.; Ycas, J.; Raichlen, J.S. Lipid levels after acute coronary syndromes. J. Am. Coll. Cardiol., 2008, 51(15), 1440-1445.
[43]
Riwanto, M.; Rohrer, L.; Roschitzki, B.; Besler, C.; Mocharla, P.; Mueller, M.; Perisa, D.; Heinrich, K.; Altwegg, L.; von Eckardstein, A.; Lüscher, T.F.; Landmesser, U. Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation, 2013, 127(8), 891-904.
[44]
Alwaili, K.; Bailey, D.; Awan, Z.; Bailey, S.D.; Ruel, I.; Hafiane, A.; Krimbou, L.; Laboissiere, S.; Genest, J. The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochim. Biophys. Acta, 2012, 1821(3), 405-415.
[45]
Tan, Y.; Liu, T.R.; Hu, S.W.; Tian, D.; Li, C.; Zhong, J.K.; Sun, H.G.; Luo, T.T.; Lai, W.Y.; Guo, Z.G. Acute coronary syndrome remodels the protein cargo and functions of high-density lipoprotein subfractions. PLoS One, 2014, 9(4), e94264.
[46]
Dullaart, R.P.; Tietge, U.J.; Kwakernaak, A.J.; Dikkeschei, B.D.; Perton, F.; Tio, R.A. Alterations in plasma lecithin: cholesterol acyltransferase and myeloperoxidase in acute myocardial infarction: implications for cardiac outcome. Atherosclerosis, 2014, 234(1), 185-192.
[47]
Besler, C.; Heinrich, K.; Rohrer, L.; Doerries, C.; Riwanto, M.; Shih, D.M.; Chroni, A.; Yonekawa, K.; Stein, S.; Schaefer, N.; Mueller, M.; Akhmedov, A.; Daniil, G.; Manes, C.; Templin, C.; Wyss, C.; Maier, W.; Tanner, F.C.; Matter, C.M.; Corti, R.; Furlong, C.; Lusis, A.J.; von Eckardstein, A.; Fogelman, A.M.; Lüscher, T.F.; Landmesser, U. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J. Clin. Invest., 2011, 121(7), 2693-2708.
[48]
Carnuta, M.G.; Stancu, C.S.; Toma, L.; Sanda, G.M.; Niculescu, L.S.; Deleanu, M.; Popescu, A.C.; Popescu, M.R.; Vlad, A.; Dimulescu, D.R.; Simionescu, M.; Sima, A.V. Dysfunctional high-density lipoproteins have distinct composition, diminished anti-inflammatory potential and discriminate acute coronary syndrome from stable coronary artery disease patients. Sci. Rep., 2017, 7(1), 7295.
[49]
Zewinger, S.; Drechsler, C.; Kleber, M.E.; Dressel, A.; Riffel, J.; Triem, S.; Lehmann, M.; Kopecky, C.; Säemann, M.D.; Lepper, P.M.; Silbernagel, G.; Scharnagl, H.; Ritsch, A.; Thorand, B.; de las Heras Gala, T.; Wagenpfeil, S.; Koenig, W.; Peters, A.; Laufs, U.; Wanner, C.; Fliser, D.; Speer, T.; März, W. Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk. Eur. Heart J., 2015, 36(43), 3007-3016.
[50]
Holy, E.W.; Besler, C.; Reiner, M.F.; Camici, G.G.; Manz, J.; Beer, J.H.; Lüscher, T.F.; Landmesser, U.; Tanner, F.C. High-density lipoprotein from patients with coronary heart disease loses anti-thrombotic effects on endothelial cells: impact on arterial thrombus formation. Thromb. Haemost., 2014, 112(5), 1024-1035.
[51]
Riwanto, M.; Landmesser, U. High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. J. Lipid Res., 2013, 54(12), 3227-3243.
[52]
Ossoli, A.; Remaley, A.T.; Vaisman, B.; Calabresi, L.; Gomaraschi, M. Plasma-derived and synthetic high-density lipoprotein inhibit tissue factor in endothelial cells and monocytes. Biochem. J., 2016, 473(2), 211-219.
[53]
Song, C.; Shen, Y.; Yamen, E.; Hsu, K.; Yan, W.; Witting, P.K.; Geczy, C.L.; Freedman, S.B. Serum amyloid A may potentiate prothrombotic and proinflammatory events in acute coronary syndromes. Atherosclerosis, 2009, 202(2), 596-604.
[54]
Tselepis, A.D.; Tsoumani, M.E.; Kalantzi, K.I.; Dimitriou, A.A.; Tellis, C.C.; Goudevenos, I.A. Influence of high-density lipoprotein and paraoxonase-1 on platelet reactivity in patients with acute coronary syndromes receiving clopidogrel therapy. J. Thromb. Haemost., 2011, 9(12), 2371-2378.
[55]
Francis, G.A. The complexity of HDL. Biochim. Biophys. Acta, 2010, 1801(12), 1286-1293.
[56]
Dullaart, R.P.; Annema, W.; Tio, R.A.; Tietge, U.J. The HDL anti-inflammatory function is impaired in myocardial infarction and may predict new cardiac events independent of HDL cholesterol. Clin. Chim. Acta, 2014, 433, 34-38.
[57]
Annema, W.; Willemsen, H.M.; de Boer, J.F.; Dikkers, A.; van der Giet, M.; Nieuwland, W.; Muller Kobold, A.C.; van Pelt, L.J.; Slart, R.H.; van der Horst, I.C.; Dullaart, R.P.; Tio, R.A.; Tietge, U.J. HDL function is impaired in acute myocardial infarction independent of plasma HDL cholesterol levels. J. Clin. Lipidol., 2016, 10(6), 1318-1328.
[58]
Undurti, A.; Huang, Y.; Lupica, J.A.; Smith, J.D.; DiDonato, J.A.; Hazen, S.L. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J. Biol. Chem., 2009, 284(45), 30825-30835.
[59]
Kontush, A. HDL-mediated mechanisms of protection in cardiovascular disease. Cardiovasc. Res., 2014, 103(3), 341-349.
[60]
Patel, P.J.; Khera, A.V.; Jafri, K.; Wilensky, R.L.; Rader, D.J. The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J. Am. Coll. Cardiol., 2011, 58(20), 2068-2075.
[61]
Bounafaa, A.; Berrougui, H.; Ikhlef, S.; Essamadi, A.; Nasser, B.; Bennis, A.; Yamoul, N.; Ghalim, N.; Khalil, A. Alteration of HDL functionality and PON1 activities in acute coronary syndrome patients. Clin. Biochem., 2014, 47(18), 318-325.
[62]
Chiba, T.; Chang, M.Y.; Wang, S.; Wight, T.N.; McMillen, T.S.; Oram, J.F.; Vaisar, T.; Heinecke, J.W.; De Beer, F.C.; De Beer, M.C.; Chait, A. Serum amyloid A facilitates the binding of high-density lipoprotein from mice injected with lipopolysaccharide to vascular proteoglycans. Arterioscler. Thromb. Vasc. Biol., 2011, 31(6), 1326-1332.
[63]
Huang, Y.; Wu, Z.; Riwanto, M.; Gao, S.; Levison, B.S.; Gu, X.; Fu, X.; Wagner, M.A.; Besler, C.; Gerstenecker, G.; Zhang, R.; Li, X.M.; DiDonato, A.J.; Gogonea, V.; Tang, W.H.; Smith, J.D.; Plow, E.F.; Fox, P.L.; Shih, D.M.; Lusis, A.J.; Fisher, E.A.; DiDonato, J.A.; Landmesser, U.; Hazen, S.L. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J. Clin. Invest., 2013, 123(9), 3815-3828.
[64]
Nofer, J.R.; Levkau, B.; Wolinska, I.; Junker, R.; Fobker, M.; von Eckardstein, A.; Seedorf, U.; Assmann, G. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J. Biol. Chem., 2001, 276(37), 34480-34485.
[65]
Kavo, A.E.; Rallidis, L.S.; Sakellaropoulos, G.C.; Lehr, S.; Hartwig, S.; Eckel, J.; Bozatzi, P.I.; Anastasiou-Nana, M.; Tsikrika, P.; Kypreos, K.E. Qualitative characteristics of HDL in young patients of an acute myocardial infarction. Atherosclerosis, 2012, 220(1), 257-264.
[66]
Luo, M.; Liu, A.; Wang, S.; Wang, T.; Hu, D.; Wu, S.; Peng, D. ApoC III enrichment in HDL impairs HDL-mediated cholesterol efflux capacity. Sci. Rep., 2017, 7(1), 2312.
[67]
Sutter, I.; Velagapudi, S.; Othman, A.; Riwanto, M.; Manz, J.; Rohrer, L.; Rentsch, K.; Hornemann, T.; Landmesser, U.; von Eckardstein, A. Plasmalogens of high-density lipoproteins (HDL) are associated with coronary artery disease and anti-apoptotic activity of HDL. Atherosclerosis, 2015, 241(2), 539-546.
[68]
Hafiane, A.; Jabor, B.; Ruel, I.; Ling, J.; Genest, J. High-density lipoprotein mediated cellular cholesterol efflux in acute coronary syndromes. Am. J. Cardiol., 2014, 113(2), 249-255.
[69]
Rached, F.; Lhomme, M.; Camont, L.; Gomes, F.; Dauteuille, C.; Robillard, P.; Santos, R.D.; Lesnik, P.; Serrano, C.V., Jr; Chapman, M.J.; Kontush, A. Defective functionality of small, dense HDL3 subpopulations in ST segment elevation myocardial infarction: Relevance of enrichment in lysophosphatidylcholine, phosphatidic acid and serum amyloid A. Biochim. Biophys. Acta, 2015, 1851(9), 1254-1261.
[70]
Shao, B.; Tang, C.; Sinha, A.; Mayer, P.S.; Davenport, G.D.; Brot, N.; Oda, M.N.; Zhao, X.Q.; Heinecke, J.W. Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase. Circ. Res., 2014, 114(11), 1733-1742.
[71]
Banka, C.L.; Yuan, T.; de Beer, M.C.; Kindy, M.; Curtiss, L.K.; de Beer, F.C. Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J. Lipid Res., 1995, 36(5), 1058-1065.
[72]
Shao, B.; Pennathur, S.; Pagani, I.; Oda, M.N.; Witztum, J.L.; Oram, J.F.; Heinecke, J.W. Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol efflux by the ABCA1 pathway. J. Biol. Chem., 2010, 285(24), 18473-18484.
[73]
Zheng, L.; Settle, M.; Brubaker, G.; Schmitt, D.; Hazen, S.L.; Smith, J.D.; Kinter, M. Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J. Biol. Chem., 2005, 280(1), 38-47.
[74]
Shao, B.; Tang, C.; Heinecke, J.W.; Oram, J.F. Oxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol export. J. Lipid Res., 2010, 51(7), 1849-1858.
[75]
Kotur-Stevuljevic, J.; Bogavac-Stanojevic, N.; Jelic-Ivanovic, Z.; Stefanovic, A.; Gojkovic, T.; Joksic, J.; Sopic, M.; Gulan, B.; Janac, J.; Milosevic, S. Oxidative stress and paraoxonase 1 status in acute ischemic stroke patients. Atherosclerosis, 2015, 241(1), 192-198.
[76]
Ortiz-Munoz, G.; Couret, D.; Lapergue, B.; Bruckert, E.; Meseguer, E.; Amarenco, P.; Meilhac, O. Dysfunctional HDL in acute stroke. Atherosclerosis, 2016, 253, 75-80.
[77]
Go, A.S.; Chertow, G.M.; Fan, D.; McCulloch, C.E.; Hsu, C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med., 2004, 351(13), 1296-1305.
[78]
Foley, R.N.; Parfrey, P.S.; Sarnak, M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis., 1998, 32(5)(Suppl. 3), S112-S119.
[79]
Shao, B.; Heinecke, J.W. Impact of HDL oxidation by the myeloperoxidase system on sterol efflux by the ABCA1 pathway. J. Proteomics, 2011, 74(11), 2289-2299.
[80]
Calabresi, L.; Simonelli, S.; Conca, P.; Busnach, G.; Cabibbe, M.; Gesualdo, L.; Gigante, M.; Penco, S.; Veglia, F.; Franceschini, G. Acquired lecithin: cholesterol acyltransferase deficiency as a major factor in lowering plasma HDL levels in chronic kidney disease. J. Intern. Med., 2015, 277(5), 552-561.
[81]
Liang, K.; Vaziri, N.D. Down-regulation of hepatic lipase expression in experimental nephrotic syndrome. Kidney Int., 1997, 51(6), 1933-1937.
[82]
Holzer, M.; Schilcher, G.; Curcic, S.; Trieb, M.; Ljubojevic, S.; Stojakovic, T.; Scharnagl, H.; Kopecky, C.M.; Rosenkranz, A.R.; Heinemann, A.; Marsche, G. Dialysis modalities and HDL composition and function. J. Am. Soc. Nephrol., 2015, 26(9), 2267-2276.
[83]
Kon, V.; Yang, H.; Fazio, S. Residual cardiovascular risk in chronic kidney disease: role of high-density lipoprotein. Arch. Med. Res., 2015, 46(5), 379-391.
[84]
Kennedy, D.J.; Tang, W.H.; Fan, Y.; Wu, Y.; Mann, S.; Pepoy, M.; Hazen, S.L. Diminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney disease. J. Am. Heart Assoc., 2013, 2(2), e000104.
[85]
Zheng, L.; Nukuna, B.; Brennan, M.L.; Sun, M.; Goormastic, M.; Settle, M.; Schmitt, D.; Fu, X.; Thomson, L.; Fox, P.L.; Ischiropoulos, H.; Smith, J.D.; Kinter, M.; Hazen, S.L. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest., 2004, 114(4), 529-541.
[86]
Rye, K.A. Biomarkers associated with high-density lipoproteins in atherosclerotic kidney disease. Clin. Exp. Nephrol., 2014, 18(2), 247-250.
[87]
Terrier-Lenglet, A.; Nollet, A.; Liabeuf, S.; Barreto, D.V.; Brazier, M.; Lemke, H.D.; Vanholder, R.; Choukroun, G.; Massy, Z.A. [Plasma malondialdehyde may not predict mortality in patient with chronic kidney disease]. Nephrol. Ther., 2011, 7(4), 219-224.
[88]
Speer, T.; Rohrer, L.; Blyszczuk, P.; Shroff, R.; Kuschnerus, K.; Kränkel, N.; Kania, G.; Zewinger, S.; Akhmedov, A.; Shi, Y.; Martin, T.; Perisa, D.; Winnik, S.; Müller, M.F.; Sester, U.; Wernicke, G.; Jung, A.; Gutteck, U.; Eriksson, U.; Geisel, J.; Deanfield, J.; von Eckardstein, A.; Lüscher, T.F.; Fliser, D.; Bahlmann, F.H.; Landmesser, U. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity, 2013, 38(4), 754-768.
[89]
Shroff, R.; Speer, T.; Colin, S.; Charakida, M.; Zewinger, S.; Staels, B.; Chinetti-Gbaguidi, G.; Hettrich, I.; Rohrer, L.; O’Neill, F.; McLoughlin, E.; Long, D.; Shanahan, C.M.; Landmesser, U.; Fliser, D.; Deanfield, J.E. HDL in children with CKD promotes endothelial dysfunction and an abnormal vascular phenotype. J. Am. Soc. Nephrol., 2014, 25(11), 2658-2668.
[90]
El-Gamal, D.; Rao, S.P.; Holzer, M.; Hallström, S.; Haybaeck, J.; Gauster, M.; Wadsack, C.; Kozina, A.; Frank, S.; Schicho, R.; Schuligoi, R.; Heinemann, A.; Marsche, G. The urea decomposition product cyanate promotes endothelial dysfunction. Kidney Int., 2014, 86(5), 923-931.
[91]
Yamamoto, S.; Yancey, P.G.; Ikizler, T.A.; Jerome, W.G.; Kaseda, R.; Cox, B.; Bian, A.; Shintani, A.; Fogo, A.B.; Linton, M.F.; Fazio, S.; Kon, V. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J. Am. Coll. Cardiol., 2012, 60(23), 2372-2379.
[92]
Kaseda, R.; Jabs, K.; Hunley, T.E.; Jones, D.; Bian, A.; Allen, R.M.; Vickers, K.C.; Yancey, P.G.; Linton, M.F.; Fazio, S.; Kon, V. Dysfunctional high-density lipoproteins in children with chronic kidney disease. Metabolism, 2015, 64(2), 263-273.
[93]
Nobécourt, E.; Tabet, F.; Lambert, G.; Puranik, R.; Bao, S.; Yan, L.; Davies, M.J.; Brown, B.E.; Jenkins, A.J.; Dusting, G.J.; Bonnet, D.J.; Curtiss, L.K.; Barter, P.J.; Rye, K.A. Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler. Thromb. Vasc. Biol., 2010, 30(4), 766-772.
[94]
Weichhart, T.; Kopecky, C.; Kubicek, M.; Haidinger, M.; Döller, D.; Katholnig, K.; Suarna, C.; Eller, P.; Tölle, M.; Gerner, C.; Zlabinger, G.J.; van der Giet, M.; Hörl, W.H.; Stocker, R.; Säemann, M.D. Serum amyloid A in uremic HDL promotes inflammation. J. Am. Soc. Nephrol., 2012, 23(5), 934-947.
[95]
Morena, M.; Cristol, J.P.; Dantoine, T.; Carbonneau, M.A.; Descomps, B.; Canaud, B. Protective effects of high-density lipoprotein against oxidative stress are impaired in haemodialysis patients. Nephrol. Dial. Transplant., 2000, 15(3), 389-395.
[96]
Moradi, H.; Pahl, M.V.; Elahimehr, R.; Vaziri, N.D. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl. Res., 2009, 153(2), 77-85.
[97]
Tölle, M.; Pawlak, A.; Schuchardt, M.; Kawamura, A.; Tietge, U.J.; Lorkowski, S.; Keul, P.; Assmann, G.; Chun, J.; Levkau, B.; van der Giet, M.; Nofer, J.R. HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler. Thromb. Vasc. Biol., 2008, 28(8), 1542-1548.
[98]
Nicholls, S.J.; Zheng, L.; Hazen, S.L. Formation of dysfunctional high-density lipoprotein by myeloperoxidase. Trends Cardiovasc. Med., 2005, 15(6), 212-219.
[99]
Holzer, M.; Birner-Gruenberger, R.; Stojakovic, T.; El-Gamal, D.; Binder, V.; Wadsack, C.; Heinemann, A.; Marsche, G. Uremia alters HDL composition and function. J. Am. Soc. Nephrol., 2011, 22(9), 1631-1641.
[100]
Meier, S.M.; Wultsch, A.; Hollaus, M.; Ammann, M.; Pemberger, E.; Liebscher, F.; Lambers, B.; Fruhwürth, S.; Stojakovic, T.; Scharnagl, H.; Schmidt, A.; Springer, A.; Becker, J.; Aufricht, C.; Handisurya, A.; Kapeller, S.; Röhrl, C.; Stangl, H.; Strobl, W. Effect of chronic kidney disease on macrophage cholesterol efflux. Life Sci., 2015, 136, 1-6.
[101]
Holzer, M.; Gauster, M.; Pfeifer, T.; Wadsack, C.; Fauler, G.; Stiegler, P.; Koefeler, H.; Beubler, E.; Schuligoi, R.; Heinemann, A.; Marsche, G. Protein carbamylation renders high-density lipoprotein dysfunctional. Antioxid. Redox Signal., 2011, 14(12), 2337-2346.
[102]
Ganda, A.; Yvan-Charvet, L.; Zhang, Y.; Lai, E.J.; Regunathan-Shenk, R.; Hussain, F.N.; Avasare, R.; Chakraborty, B.; Febus, A.J.; Vernocchi, L.; Lantigua, R.; Wang, Y.; Shi, X.; Hsieh, J.; Murphy, A.J.; Wang, N.; Bijl, N.; Gordon, K.M.; de Miguel, M.H.; Singer, J.R.; Hogan, J.; Cremers, S.; Magnusson, M.; Melander, O.; Gerszten, R.E.; Tall, A.R. Plasma metabolite profiles, cellular cholesterol efflux, and non-traditional cardiovascular risk in patients with CKD. J. Mol. Cell. Cardiol., 2017, 112, 114-122.
[103]
Cardinal, H.; Raymond, M.A.; Hébert, M.J.; Madore, F. Uraemic plasma decreases the expression of ABCA1, ABCG1 and cell-cycle genes in human coronary arterial endothelial cells. Nephrol. Dial. Transplant., 2007, 22(2), 409-416.
[104]
Lewis, G.F.; Rader, D.J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res., 2005, 96(12), 1221-1232.
[105]
Lagos, K.G.; Filippatos, T.D.; Tsimihodimos, V.; Gazi, I.F.; Rizos, C.; Tselepis, A.D.; Mikhailidis, D.P.; Elisaf, M.S. Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids, 2009, 44(1), 9-16.
[106]
Guérin, M.; Le Goff, W.; Lassel, T.S.; Van Tol, A.; Steiner, G.; Chapman, M.J. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler. Thromb. Vasc. Biol., 2001, 21(2), 282-288.
[107]
Rashid, S.; Barrett, P.H.; Uffelman, K.D.; Watanabe, T.; Adeli, K.; Lewis, G.F. Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation. Arterioscler. Thromb. Vasc. Biol., 2002, 22(3), 483-487.
[108]
Fielding, C.J.; Reaven, G.M.; Liu, G.; Fielding, P.E. Increased free cholesterol in plasma low and very low density lipoproteins in non-insulin-dependent diabetes mellitus: its role in the inhibition of cholesteryl ester transfer. Proc. Natl. Acad. Sci. USA, 1984, 81(8), 2512-2516.
[109]
Dullaart, R.P.; Riemens, S.C.; Scheek, L.M.; Van Tol, A. Insulin decreases plasma cholesteryl ester transfer but not cholesterol esterification in healthy subjects as well as in normotriglyceridaemic patients with type 2 diabetes. Eur. J. Clin. Invest., 1999, 29(8), 663-671.
[110]
Hansel, B.; Giral, P.; Nobecourt, E.; Chantepie, S.; Bruckert, E.; Chapman, M.J.; Kontush, A. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J. Clin. Endocrinol. Metab., 2004, 89(10), 4963-4971.
[111]
Camont, L.; Lhomme, M.; Rached, F.; Le Goff, W.; Nègre-Salvayre, A.; Salvayre, R.; Calzada, C.; Lagarde, M.; Chapman, M.J.; Kontush, A. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler. Thromb. Vasc. Biol., 2013, 33(12), 2715-2723.
[112]
Bagdade, J.D.; Buchanan, W.E.; Kuusi, T.; Taskinen, M.R. Persistent abnormalities in lipoprotein composition in noninsulin-dependent diabetes after intensive insulin therapy. Arteriosclerosis, 1990, 10(2), 232-239.
[113]
Watala, C.; Winocour, P.D. The relationship of chemical modification of membrane proteins and plasma lipoproteins to reduced membrane fluidity of erythrocytes from diabetic subjects. Eur. J. Clin. Chem. Clin. Biochem., 1992, 30(9), 513-519.
[114]
Denimal, D.; Monier, S.; Brindisi, M.C.; Petit, J.M.; Bouillet, B.; Nguyen, A.; Demizieux, L.; Simoneau, I.; Pais de Barros, J.P.; Vergès, B.; Duvillard, L. Impairment of the ability of HDL from patients with metabolic syndrome but without diabetes mellitus to activate eNOS: correction by S1P enrichment. Arterioscler. Thromb. Vasc. Biol., 2017, 37(5), 804-811.
[115]
Brinck, J.W.; Thomas, A.; Lauer, E.; Jornayvaz, F.R.; Brulhart-Meynet, M.C.; Prost, J.C.; Pataky, Z.; Löfgren, P.; Hoffstedt, J.; Eriksson, M.; Pramfalk, C.; Morel, S.; Kwak, B.R.; van Eck, M.; James, R.W.; Frias, M.A. Diabetes mellitus is associated with reduced high-density lipoprotein sphingosine-1-phosphate content and impaired high-density lipoprotein cardiac cell protection. Arterioscler. Thromb. Vasc. Biol., 2016, 36(5), 817-824.
[116]
Ceriello, A.; Motz, E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler. Thromb. Vasc. Biol., 2004, 24(5), 816-823.
[117]
Khovidhunkit, W.; Kim, M.S.; Memon, R.A.; Shigenaga, J.K.; Moser, A.H.; Feingold, K.R.; Grunfeld, C. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res., 2004, 45(7), 1169-1196.
[118]
Curtiss, L.K.; Bonnet, D.J.; Rye, K.A. The conformation of apolipoprotein A-I in high-density lipoproteins is influenced by core lipid composition and particle size: a surface plasmon resonance study. Biochemistry, 2000, 39(19), 5712-5721.
[119]
Kontush, A.; de Faria, E.C.; Chantepie, S.; Chapman, M.J. A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity. Atherosclerosis, 2005, 182(2), 277-285.
[120]
Shao, B.; Oda, M.N.; Oram, J.F.; Heinecke, J.W. Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr. Opin. Cardiol., 2006, 21(4), 322-328.
[121]
Hermo, R.; Mier, C.; Mazzotta, M.; Tsuji, M.; Kimura, S.; Gugliucci, A. Circulating levels of nitrated apolipoprotein A-I are increased in type 2 diabetic patients. Clin. Chem. Lab. Med., 2005, 43(6), 601-606.
[122]
Karabina, S.A.; Lehner, A.N.; Frank, E.; Parthasarathy, S.; Santanam, N. Oxidative inactivation of paraoxonase--implications in diabetes mellitus and atherosclerosis. Biochim. Biophys. Acta, 2005, 1725(2), 213-221.
[123]
Ferretti, G.; Bacchetti, T.; Marchionni, C.; Caldarelli, L.; Curatola, G. Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol., 2001, 38(4), 163-169.
[124]
Durrington, P.N.; Mackness, B.; Mackness, M.I. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2001, 21(4), 473-480.
[125]
Boemi, M.; Leviev, I.; Sirolla, C.; Pieri, C.; Marra, M.; James, R.W. Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis, 2001, 155(1), 229-235.
[126]
Perségol, L.; Vergès, B.; Foissac, M.; Gambert, P.; Duvillard, L. Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia, 2006, 49(6), 1380-1386.
[127]
Meyer, M.F.; Lieps, D.; Schatz, H.; Pfohl, M. Impaired flow-mediated vasodilation in type 2 diabetes: lack of relation to microvascular dysfunction. Microvasc. Res., 2008, 76(1), 61-65.
[128]
Wen, Y.; Skidmore, J.C.; Porter-Turner, M.M.; Rea, C.A.; Khokher, M.A.; Singh, B.M. Relationship of glycation, antioxidant status and oxidative stress to vascular endothelial damage in diabetes. Diabetes Obes. Metab., 2002, 4(5), 305-308.
[129]
Lemmers, R.F.H.; van Hoek, M.; Lieverse, A.G.; Verhoeven, A.J.M.; Sijbrands, E.J.G.; Mulder, M.T. The anti-inflammatory function of high-density lipoprotein in type II diabetes: A systematic review. J. Clin. Lipidol., 2017, 11(3), 712-724.e5.
[130]
Hedrick, C.C.; Thorpe, S.R.; Fu, M.X.; Harper, C.M.; Yoo, J.; Kim, S.M.; Wong, H.; Peters, A.L. Glycation impairs high-density lipoprotein function. Diabetologia, 2000, 43(3), 312-320.
[131]
Hoang, A.; Murphy, A.J.; Coughlan, M.T.; Thomas, M.C.; Forbes, J.M.; O’Brien, R.; Cooper, M.E.; Chin-Dusting, J.P.; Sviridov, D. Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia, 2007, 50(8), 1770-1779.
[132]
Kontush, A.; Chapman, M.J. Antiatherogenic small, dense HDL--guardian angel of the arterial wall? Nat. Clin. Pract. Cardiovasc. Med., 2006, 3(3), 144-153.
[133]
Nobécourt, E.; Jacqueminet, S.; Hansel, B.; Chantepie, S.; Grimaldi, A.; Chapman, M.J.; Kontush, A. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia, 2005, 48(3), 529-538.
[134]
Gowri, M.S.; Van der Westhuyzen, D.R.; Bridges, S.R.; Anderson, J.W. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may Be due to the abnormal composition of HDL. Arterioscler. Thromb. Vasc. Biol., 1999, 19(9), 2226-2233.
[135]
Lakshman, M.R.; Gottipati, C.S.; Narasimhan, S.J.; Munoz, J.; Marmillot, P.; Nylen, E.S. Inverse correlation of serum paraoxonase and homocysteine thiolactonase activities and antioxidant capacity of high-density lipoprotein with the severity of cardiovascular disease in persons with type 2 diabetes mellitus. Metabolism, 2006, 55(9), 1201-1206.
[136]
Van Lenten, B.J.; Navab, M.; Shih, D.; Fogelman, A.M.; Lusis, A.J. The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc. Med., 2001, 11(3-4), 155-161.
[137]
Zerrad-Saadi, A.; Therond, P.; Chantepie, S.; Couturier, M.; Rye, K.A.; Chapman, M.J.; Kontush, A. HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis. Arterioscler. Thromb. Vasc. Biol., 2009, 29(12), 2169-2175.
[138]
Mastorikou, M.; Mackness, M.; Mackness, B. Defective metabolism of oxidized phospholipid by HDL from people with type 2 diabetes. Diabetes, 2006, 55(11), 3099-3103.
[139]
Gomez Rosso, L.; Lhomme, M.; Meroño, T.; Dellepiane, A.; Sorroche, P.; Hedjazi, L.; Zakiev, E.; Sukhorukov, V.; Orekhov, A.; Gasparri, J.; Chapman, M.J.; Brites, F.; Kontush, A. Poor glycemic control in type 2 diabetes enhances functional and compositional alterations of small, dense HDL3c. Biochim Biophys Acta Mol Cell Biol Lipids, 2017, 1862(2), 188-195.
[140]
Dullaart, R.P.; de Boer, J.F.; Annema, W.; Tietge, U.J. The inverse relation of HDL anti-oxidative functionality with serum amyloid a is lost in metabolic syndrome subjects. Obesity (Silver Spring), 2013, 21(2), 361-366.
[141]
Sanguinetti, S.M.; Brites, F.D.; Fasulo, V.; Verona, J.; Elbert, A.; Wikinski, R.L.; Schreier, L.E. HDL oxidability and its protective effect against LDL oxidation in Type 2 diabetic patients. Diabetes Nutr. Metab., 2001, 14(1), 27-36.
[142]
Matsunaga, T.; Iguchi, K.; Nakajima, T.; Koyama, I.; Miyazaki, T.; Inoue, I.; Kawai, S.; Katayama, S.; Hirano, K.; Hokari, S.; Komoda, T. Glycated high-density lipoprotein induces apoptosis of endothelial cells via a mitochondrial dysfunction. Biochem. Biophys. Res. Commun., 2001, 287(3), 714-720.
[143]
Cavallero, E.; Brites, F.; Delfly, B.; Nicolaïew, N.; Decossin, C.; De Geitere, C.; Fruchart, J.C.; Wikinski, R.; Jacotot, B.; Castro, G. Abnormal reverse cholesterol transport in controlled type II diabetic patients. Studies on fasting and postprandial LpA-I particles. Arterioscler. Thromb. Vasc. Biol., 1995, 15(12), 2130-2135.
[144]
Syvänne, M.; Castro, G.; Dengremont, C.; De Geitere, C.; Jauhiainen, M.; Ehnholm, C.; Michelagnoli, S.; Franceschini, G.; Kahri, J.; Taskinen, M.R. Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein. Atherosclerosis, 1996, 127(2), 245-253.
[145]
Igau, B.; Castro, G.; Clavey, V.; Slomianny, C.; Bresson, R.; Drouin, P.; Fruchart, J.C.; Fiévet, C. In vivo glucosylated LpA-I subfraction. Evidence for structural and functional alterations. Arterioscler. Thromb. Vasc. Biol., 1997, 17(11), 2830-2836.
[146]
Fievet, C.; Theret, N.; Shojaee, N.; Duchateau, P.; Castro, G.; Ailhaud, G.; Drouin, P.; Fruchart, J.C. Apolipoprotein A-I-containing particles and reverse cholesterol transport in IDDM. Diabetes, 1992, 41(Suppl. 2), 81-85.
[147]
Yancey, P.G.; de la Llera-Moya, M.; Swarnakar, S.; Monzo, P.; Klein, S.M.; Connelly, M.A.; Johnson, W.J.; Williams, D.L.; Rothblat, G.H. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J. Biol. Chem., 2000, 275(47), 36596-36604.
[148]
Annema, W.; Dikkers, A.; de Boer, J.F.; van Greevenbroek, M.M.; van der Kallen, C.J.; Schalkwijk, C.G.; Stehouwer, C.D.; Dullaart, R.P.; Tietge, U.J. Impaired HDL cholesterol efflux in metabolic syndrome is unrelated to glucose tolerance status: the CODAM study. Sci. Rep., 2016, 6, 27367.
[149]
Lucero, D.; Sviridov, D.; Freeman, L.; López, G.I.; Fassio, E.; Remaley, A.T.; Schreier, L. Increased cholesterol efflux capacity in metabolic syndrome: Relation with qualitative alterations in HDL and LCAT. Atherosclerosis, 2015, 242(1), 236-242.
[150]
Dullaart, R.P.; Groen, A.K.; Dallinga-Thie, G.M.; de Vries, R.; Sluiter, W.J.; van Tol, A. Fibroblast cholesterol efflux to plasma from metabolic syndrome subjects is not defective despite low high-density lipoprotein cholesterol. Eur. J. Endocrinol., 2008, 158(1), 53-60.
[151]
Avina-Zubieta, J.A.; Thomas, J.; Sadatsafavi, M.; Lehman, A.J.; Lacaille, D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann. Rheum. Dis., 2012, 71(9), 1524-1529.
[152]
Fransen, J.; Kazemi-Bajestani, S.M.; Bredie, S.J.; Popa, C.D. Rheumatoid arthritis disadvantages younger patients for cardiovascular diseases: a meta-analysis. PLoS One, 2016, 11(6), e0157360.
[153]
Charakida, M.; Besler, C.; Batuca, J.R.; Sangle, S.; Marques, S.; Sousa, M.; Wang, G.; Tousoulis, D.; Delgado Alves, J.; Loukogeorgakis, S.P.; Mackworth-Young, C.; D’Cruz, D.; Luscher, T.; Landmesser, U.; Deanfield, J.E. Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA, 2009, 302(11), 1210-1217.
[154]
Botta, E.; Meroño, T.; Saucedo, C.; Martín, M.; Tetzlaff, W.; Sorroche, P.; Boero, L.; Malah, V.; Menafra, M.; Gómez Rosso, L.; Chapman, J.M.; Kontush, A.; Soriano, E.; Brites, F. Associations between disease activity, markers of HDL functionality and arterial stiffness in patients with rheumatoid arthritis. Atherosclerosis, 2016, 251, 438-444.
[155]
Baghdadi, L.R.; Woodman, R.J.; Shanahan, E.M.; Mangoni, A.A. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One, 2015, 10(2), e0117952.
[156]
González-Gay, M.A.; González-Juanatey, C. Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox. Ann. Rheum. Dis., 2014, 73(7), 1281-1283.
[157]
Mathieu, S.; Gossec, L.; Dougados, M.; Soubrier, M. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res. (Hoboken), 2011, 63(4), 557-563.
[158]
McMahon, M.; Grossman, J.; Skaggs, B.; Fitzgerald, J.; Sahakian, L.; Ragavendra, N.; Charles-Schoeman, C.; Watson, K.; Wong, W.K.; Volkmann, E.; Chen, W.; Gorn, A.; Karpouzas, G.; Weisman, M.; Wallace, D.J.; Hahn, B.H. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum., 2009, 60(8), 2428-2437.
[159]
Charles-Schoeman, C.; Watanabe, J.; Lee, Y.Y.; Furst, D.E.; Amjadi, S.; Elashoff, D.; Park, G.; McMahon, M.; Paulus, H.E.; Fogelman, A.M.; Reddy, S.T. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum., 2009, 60(10), 2870-2879.
[160]
Gómez Rosso, L.; Lhomme, M.; Meroño, T.; Sorroche, P.; Catoggio, L.; Soriano, E.; Saucedo, C.; Malah, V.; Dauteuille, C.; Boero, L.; Lesnik, P.; Robillard, P.; John Chapman, M.; Brites, F.; Kontush, A. Altered lipidome and antioxidative activity of small, dense HDL in normolipidemic rheumatoid arthritis: relevance of inflammation. Atherosclerosis, 2014, 237(2), 652-660.
[161]
Jorissen, W.; Wouters, E.; Bogie, J.F.; Vanmierlo, T.; Noben, J.P.; Sviridov, D.; Hellings, N.; Somers, V.; Valcke, R.; Vanwijmeersch, B.; Stinissen, P.; Mulder, M.T.; Remaley, A.T.; Hendriks, J.J. Relapsing-remitting multiple sclerosis patients display an altered lipoprotein profile with dysfunctional HDL. Sci. Rep., 2017, 7, 43410.
[162]
Charles-Schoeman, C.; Lee, Y.Y.; Grijalva, V.; Amjadi, S.; FitzGerald, J.; Ranganath, V.K.; Taylor, M.; McMahon, M.; Paulus, H.E.; Reddy, S.T. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann. Rheum. Dis., 2012, 71(7), 1157-1162.
[163]
Vivekanandan-Giri, A.; Slocum, J.L.; Byun, J.; Tang, C.; Sands, R.L.; Gillespie, B.W.; Heinecke, J.W.; Saran, R.; Kaplan, M.J.; Pennathur, S. High density lipoprotein is targeted for oxidation by myeloperoxidase in rheumatoid arthritis. Ann. Rheum. Dis., 2013, 72(10), 1725-1731.
[164]
Tejera-Segura, B.; Macía-Díaz, M.; Machado, J.D.; de Vera-González, A.; García-Dopico, J.A.; Olmos, J.M.; Hernández, J.L.; Díaz-González, F.; González-Gay, M.A.; Ferraz-Amaro, I. HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis. Arthritis Res. Ther., 2017, 19(1), 113.
[165]
Liao, K.P.; Playford, M.P.; Frits, M.; Coblyn, J.S.; Iannaccone, C.; Weinblatt, M.E.; Shadick, N.S.; Mehta, N.N. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J. Am. Heart Assoc., 2015, 4(2), e001588.
[166]
Ronda, N.; Favari, E.; Borghi, M.O.; Ingegnoli, F.; Gerosa, M.; Chighizola, C.; Zimetti, F.; Adorni, M.P.; Bernini, F.; Meroni, P.L. Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Ann. Rheum. Dis., 2014, 73(3), 609-615.
[167]
Krause, B.R.; Remaley, A.T. Reconstituted HDL for the acute treatment of acute coronary syndrome. Curr. Opin. Lipidol., 2013, 24(6), 480-486.
[168]
Gomaraschi, M.; Adorni, M.P.; Banach, M.; Bernini, F.; Franceschini, G.; Calabresi, L. Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function. Handb. Exp. Pharmacol., 2015, 224, 593-615.
[169]
de Vries, R.; Groen, A.K.; Perton, F.G.; Dallinga-Thie, G.M.; van Wijland, M.J.; Dikkeschei, L.D.; Wolffenbuttel, B.H.; van Tol, A.; Dullaart, R.P. Increased cholesterol efflux from cultured fibroblasts to plasma from hypertriglyceridemic type 2 diabetic patients: roles of pre beta-HDL, phospholipid transfer protein and cholesterol esterification. Atherosclerosis, 2008, 196(2), 733-741.
[170]
Sviridov, D.; Hoang, A.; Ooi, E.; Watts, G.; Barrett, P.H.; Nestel, P. Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. Atherosclerosis, 2008, 197(2), 732-739.
[171]
Miyamoto-Sasaki, M.; Yasuda, T.; Monguchi, T.; Nakajima, H.; Mori, K.; Toh, R.; Ishida, T.; Hirata, K. Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients. J. Atheroscler. Thromb., 2013, 20(9), 708-716.
[172]
Triolo, M.; Annema, W.; de Boer, J.F.; Tietge, U.J.; Dullaart, R.P. Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes. Eur. J. Clin. Invest., 2014, 44(3), 240-248.
[173]
Guerin, M.; Egger, P.; Soudant, C.; Le Goff, W.; van Tol, A.; Dupuis, R.; Chapman, M.J. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis, 2002, 163(2), 287-296.
[174]
Franceschini, G.; Calabresi, L.; Colombo, C.; Favari, E.; Bernini, F.; Sirtori, C.R. Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients. Atherosclerosis, 2007, 195(2), 385-391.
[175]
Antonopoulos, A.S.; Margaritis, M.; Lee, R.; Channon, K.; Antoniades, C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr. Pharm. Des., 2012, 18(11), 1519-1530.
[176]
Liu, Y.; Wei, J.; Hu, S.; Hu, L. Beneficial effects of statins on endothelial progenitor cells. Am. J. Med. Sci., 2012, 344(3), 220-226.
[177]
Reriani, M.K.; Dunlay, S.M.; Gupta, B.; West, C.P.; Rihal, C.S.; Lerman, L.O.; Lerman, A. Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials. Eur. J. Cardiovasc. Prev. Rehabil., 2011, 18(5), 704-716.
[178]
Igarashi, J.; Miyoshi, M.; Hashimoto, T.; Kubota, Y.; Kosaka, H. Statins induce S1P1 receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins. Br. J. Pharmacol., 2007, 150(4), 470-479.
[179]
Kimura, T.; Mogi, C.; Tomura, H.; Kuwabara, A.; Im, D.S.; Sato, K.; Kurose, H.; Murakami, M.; Okajima, F. Induction of scavenger receptor class B type I is critical for simvastatin enhancement of high-density lipoprotein-induced anti-inflammatory actions in endothelial cells. J. Immunol., 2008, 181(10), 7332-7340.
[180]
Franceschini, G.; Favari, E.; Calabresi, L.; Simonelli, S.; Bondioli, A.; Adorni, M.P.; Zimetti, F.; Gomaraschi, M.; Coutant, K.; Rossomanno, S.; Niesor, E.J.; Bernini, F.; Benghozi, R. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients. J. Clin. Lipidol., 2013, 7(5), 414-422.
[181]
Guerin, M.; Le Goff, W.; Frisdal, E.; Schneider, S.; Milosavljevic, D.; Bruckert, E.; Chapman, M.J. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux. J. Clin. Endocrinol. Metab., 2003, 88(8), 3738-3746.
[182]
Maranghi, M.; Hiukka, A.; Badeau, R.; Sundvall, J.; Jauhiainen, M.; Taskinen, M.R. Macrophage cholesterol efflux to plasma and HDL in subjects with low and high homocysteine levels: a FIELD substudy. Atherosclerosis, 2011, 219(1), 259-265.
[183]
Khera, A.V.; Patel, P.J.; Reilly, M.P.; Rader, D.J. The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality. J. Am. Coll. Cardiol., 2013, 62(20), 1909-1910.
[184]
Yvan-Charvet, L.; Kling, J.; Pagler, T.; Li, H.; Hubbard, B.; Fisher, T.; Sparrow, C.P.; Taggart, A.K.; Tall, A.R. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler. Thromb. Vasc. Biol., 2010, 30(7), 1430-1438.
[185]
Morgan, J.M.; de la Llera-Moya, M.; Capuzzi, D.M. Effects of niacin and niaspan on HDL lipoprotein cellular SR-BI-mediated cholesterol efflux. J. Clin. Lipidol., 2007, 1(6), 614-619.
[186]
Malik, J.; Melenovsky, V.; Wichterle, D.; Haas, T.; Simek, J.; Ceska, R.; Hradec, J. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT). Cardiovasc. Res., 2001, 52(2), 290-298.
[187]
Wang, T.D.; Chen, W.J.; Lin, J.W.; Cheng, C.C.; Chen, M.F.; Lee, Y.T. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis, 2003, 170(2), 315-323.
[188]
Koh, K.K.; Quon, M.J.; Han, S.H.; Chung, W.J.; Ahn, J.Y.; Seo, Y.H.; Choi, I.S.; Shin, E.K. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J. Am. Coll. Cardiol., 2005, 45(10), 1649-1653.
[189]
Calabresi, L.; Gomaraschi, M.; Villa, B.; Omoboni, L.; Dmitrieff, C.; Franceschini, G. Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol. Arterioscler. Thromb. Vasc. Biol., 2002, 22(4), 656-661.
[190]
Avogaro, A.; Miola, M.; Favaro, A.; Gottardo, L.; Pacini, G.; Manzato, E.; Zambon, S.; Sacerdoti, D.; de Kreutzenberg, S.; Piliego, T.; Tiengo, A.; Del Prato, S. Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. Eur. J. Clin. Invest., 2001, 31(7), 603-609.
[191]
Evans, M.; Anderson, R.A.; Graham, J.; Ellis, G.R.; Morris, K.; Davies, S.; Jackson, S.K.; Lewis, M.J.; Frenneaux, M.P.; Rees, A. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation, 2000, 101(15), 1773-1779.
[192]
Ghani, R.A.; Bin Yaakob, I.; Wahab, N.A.; Zainudin, S.; Mustafa, N.; Sukor, N.; Wan Mohamud, W.N.; Kadir, K.A.; Kamaruddin, N.A. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia. J. Clin. Lipidol., 2013, 7(5), 446-453.
[193]
Shinnakasu, A.; Yamamoto, K.; Kurano, M.; Arimura, H.; Arimura, A.; Kikuti, A.; Hashiguchi, H.; Deguchi, T.; Nishio, Y. The combination therapy of fenofibrate and ezetimibe improved lipid profile and vascular function compared with statins in patients with type 2 diabetes. J. Atheroscler. Thromb., 2017, 24(7), 735-748.
[194]
Kuvin, J.T.; Rämet, M.E.; Patel, A.R.; Pandian, N.G.; Mendelsohn, M.E.; Karas, R.H. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am. Heart J., 2002, 144(1), 165-172.
[195]
Kuvin, J.T.; Dave, D.M.; Sliney, K.A.; Mooney, P.; Patel, A.R.; Kimmelstiel, C.D.; Karas, R.H. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am. J. Cardiol., 2006, 98(6), 743-745.
[196]
Benjó, A.M.; Maranhão, R.C.; Coimbra, S.R.; Andrade, A.C.; Favarato, D.; Molina, M.S.; Brandizzi, L.I.; da Luz, P.L. Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment. Atherosclerosis, 2006, 187(1), 116-122.
[197]
Thoenes, M.; Oguchi, A.; Nagamia, S.; Vaccari, C.S.; Hammoud, R.; Umpierrez, G.E.; Khan, B.V. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. Int. J. Clin. Pract., 2007, 61(11), 1942-1948.
[198]
Bregar, U.; Jug, B.; Keber, I.; Cevc, M.; Sebestjen, M. Extended-release niacin/laropiprant improves endothelial function in patients after myocardial infarction. Heart Vessels, 2014, 29(3), 313-319.
[199]
Gomaraschi, M.; Ossoli, A.; Adorni, M.P.; Damonte, E.; Niesor, E.; Veglia, F.; Franceschini, G.; Benghozi, R.; Calabresi, L. Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome. Vascul. Pharmacol., 2015, 74, 80-86.
[200]
Sorrentino, S.A.; Besler, C.; Rohrer, L.; Meyer, M.; Heinrich, K.; Bahlmann, F.H.; Mueller, M.; Horváth, T.; Doerries, C.; Heinemann, M.; Flemmer, S.; Markowski, A.; Manes, C.; Bahr, M.J.; Haller, H.; von Eckardstein, A.; Drexler, H.; Landmesser, U. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation, 2010, 121(1), 110-122.
[201]
Ballantyne, C. M.; Miller, M.; Niesor, E. J.; Burgess, T.; Kallend, D.; Stein, E. A. Effect of dalcetrapib plus pravastatin
on lipoprotein metabolism and high-density lipoprotein
composition and function in dyslipidemic patients: results
of a phase IIb dose-ranging study. Am. Heart J.,, 2012, 163(3), 515-521, 521.e1-521.e3.
[202]
Ray, K.K.; Ditmarsch, M.; Kallend, D.; Niesor, E.J.; Suchankova, G.; Upmanyu, R.; Anzures-Cabrera, J.; Lehnert, V.; Pauly-Evers, M.; Holme, I.; Štásek, J.; van Hessen, M.W.; Jones, P. The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial. Eur. Heart J., 2014, 35(27), 1792-1800.
[203]
Lüscher, T.F.; Taddei, S.; Kaski, J.C.; Jukema, J.W.; Kallend, D.; Münzel, T.; Kastelein, J.J.; Deanfield, J.E. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur. Heart J., 2012, 33(7), 857-865.
[204]
Patel, S.; Drew, B.G.; Nakhla, S.; Duffy, S.J.; Murphy, A.J.; Barter, P.J.; Rye, K.A.; Chin-Dusting, J.; Hoang, A.; Sviridov, D.; Celermajer, D.S.; Kingwell, B.A. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J. Am. Coll. Cardiol., 2009, 53(11), 962-971.
[205]
Kallend, D.G.; Reijers, J.A.; Bellibas, S.E.; Bobillier, A.; Kempen, H.; Burggraaf, J.; Moerland, M.; Wijngaard, P.L. A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease. Eur. Heart J. Cardiovasc. Pharmacother., 2016, 2(1), 23-29.
[206]
Kempen, H.J.; Gomaraschi, M.; Simonelli, S.; Calabresi, L.; Moerland, M.; Otvos, J.; Jeyarajah, E.; Kallend, D.; Wijngaard, P.L.J. Persistent changes in lipoprotein lipids after a single infusion of ascending doses of MDCO-216 (apoA-IMilano/POPC) in healthy volunteers and stable coronary artery disease patients. Atherosclerosis, 2016, 255, 17-24.
[207]
Diditchenko, S.; Gille, A.; Pragst, I.; Stadler, D.; Waelchli, M.; Hamilton, R.; Leis, A.; Wright, S.D. Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. Arterioscler. Thromb. Vasc. Biol., 2013, 33(9), 2202-2211.
[208]
Kootte, R.S.; Smits, L.P.; van der Valk, F.M.; Dasseux, J.L.; Keyserling, C.H.; Barbaras, R.; Paolini, J.F.; Santos, R.D.; van Dijk, T.H.; Dallinga-van Thie, G.M.; Nederveen, A.J.; Mulder, W.J.; Hovingh, G.K.; Kastelein, J.J.; Groen, A.K.; Stroes, E.S. Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA. J. Lipid Res., 2015, 56(3), 703-712.
[209]
Zheng, K.H.; van der Valk, F.M.; Smits, L.P.; Sandberg, M.; Dasseux, J.L.; Baron, R.; Barbaras, R.; Keyserling, C.; Coolen, B.F.; Nederveen, A.J.; Verberne, H.J.; Nell, T.E.; Vugts, D.J.; Duivenvoorden, R.; Fayad, Z.A.; Mulder, W.J.M.; van Dongen, G.A.M.S.; Stroes, E.S.G. HDL mimetic CER-001 targets atherosclerotic plaques in patients. Atherosclerosis, 2016, 251, 381-388.
[210]
Calkin, A.C.; Drew, B.G.; Ono, A.; Duffy, S.J.; Gordon, M.V.; Schoenwaelder, S.M.; Sviridov, D.; Cooper, M.E.; Kingwell, B.A.; Jackson, S.P. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation, 2009, 120(21), 2095-2104.
[211]
Matsuki, K.; Tamasawa, N.; Yamashita, M.; Tanabe, J.; Murakami, H.; Matsui, J.; Imaizumi, T.; Satoh, K.; Suda, T. Metformin restores impaired HDL-mediated cholesterol efflux due to glycation. Atherosclerosis, 2009, 206(2), 434-438.
[212]
Machado, A.P.; Pinto, R.S.; Moysés, Z.P.; Nakandakare, E.R.; Quintão, E.C.; Passarelli, M. Aminoguanidine and metformin prevent the reduced rate of HDL-mediated cell cholesterol efflux induced by formation of advanced glycation end products. Int. J. Biochem. Cell Biol., 2006, 38(3), 392-403.
[213]
Ronda, N.; Greco, D.; Adorni, M.P.; Zimetti, F.; Favari, E.; Hjeltnes, G.; Mikkelsen, K.; Borghi, M.O.; Favalli, E.G.; Gatti, R.; Hollan, I.; Meroni, P.L.; Bernini, F. Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism. Arthritis Rheumatol., 2015, 67(5), 1155-1164.
[214]
Ormseth, M.J.; Yancey, P.G.; Solus, J.F.; Bridges, S.L., Jr; Curtis, J.R.; Linton, M.F.; Fazio, S.; Davies, S.S.; Roberts, L.J., II; Vickers, K.C.; Kon, V.; Michael Stein, C. Effect of drug therapy on net cholesterol efflux capacity of high-density lipoprotein-enriched serum in rheumatoid arthritis. Arthritis Rheumatol., 2016, 68(9), 2099-2105.
[215]
O’Neill, F.; Charakida, M.; Topham, E.; McLoughlin, E.; Patel, N.; Sutill, E.; Kay, C.W.M.; D’Aiuto, F.; Landmesser, U.; Taylor, P.C.; Deanfield, J. Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis. Heart, 2017, 103(10), 766-773.
[216]
Charles-Schoeman, C.; Yin , Lee. Y.; Shahbazian, A.; Wang, X.; Elashoff, D.; Curtis, J. R.; Navarro-Millán, I.; Yang, S.; Chen, L.; Cofield, S. S.; Moreland, L. W.; Paulus, H.; O’Dell, J.; Bathon, J.; Louis Bridges, S. Jr.; Reddy, S. T. Improvement of high-density lipoprotein function in patients with early rheumatoid arthritis treated with methotrexate monotherapy or combination therapies in a randomized controlled trial. Arthritis Rheumatol., 2017, 69(1), 46-57.
[217]
Nordestgaard, B.G.; Tybjærg-Hansen, A. Genetic determinants of LDL, lipoprotein(a), triglyceride-rich lipoproteins and HDL: concordance and discordance with cardiovascular disease risk. Curr. Opin. Lipidol., 2011, 22(2), 113-122.
Download PDF Flyer